The U.S. Food and Drug Administration issued draft guidance for sponsors seeking approval for targeted individualized therapies by generating substantial evidence of effectiveness and safety when randomized controlled trials are not feasible due to small patient populations. The draft guidance, issued by the Center for Biologics Evaluation and Research and Center...
